Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥2,360 JPY
Change Today +11.50 / 0.49%
Volume 1.6M
4568 On Other Exchanges
As of 10:20 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

daiichi sankyo co ltd (4568) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - ¥2,388
52 Week Low
01/16/15 - ¥1,556
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products in Japan and internationally. The company’s product portfolio includes generic pharmaceuticals, vaccines, and over-the-counter (OTC) medicines. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Edoxaban, an anticoagulant; Memary and Donepezil for the treatment of alzheimer’s disease; Nexium for treating reflux esophagitis; Pralia for osteoporosis; Tenelia for treatment for type 2 diabetes mellitus; and ActHIB, a haemophilus b conjugate vaccine, as well as Denosumab to treat and prevent various bone disorders, including osteoporosis and bone metastases. The company’s products OTC comprise Loxonin S, an analgesic and anti-inflammatory drug; Transino II, a drug for the improvement of spots; and Traful Ointment for stomatitis treatment. It also markets therapies in hypertension, dyslipidemia, and bacterial infections, as well as treatments for thrombotic disorders. In addition, the company researches and develops therapies in oncology and cardiovascular-metabolic diseases, including biologics. Further, it manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates, as well as pharmaceuticals and drugs for animals. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

16,428 Employees
Last Reported Date: 05/14/15
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥131.0M
Compensation as of Fiscal Year 2014.

daiichi sankyo co ltd (4568) Key Developments

Daiichi Sankyo Company, Limited Announces Dividend for the Year Ending March 31, 2015, Payable from June 23, 2015; Provides Dividend Guidance for the Year Ending March 31, 2016

Daiichi Sankyo Company, Limited announced that the board of directors approved a resolution on May 14, to pay a commemorative dividend to mark the company's 10th anniversary. The commemorative dividend of ¥10 per share will be paid in addition to the ordinary interim dividend of ¥30 at the end of the second quarter of fiscal 2015 (from April 1, 2015 to March 31, 2016). The company also expects to pay a year-end dividend of ¥30 per share for the year ending March 31, 2016 compared to ¥30 per share for the same period a year ago. The company announced a dividend of ¥30 per share for the year ending March 31, 2015 compared to ¥30 per share paid a year ago. Scheduled date of dividend payments is from June 23, 2015.

Daiichi Sankyo Company, Limited Reports Consolidated and Non-Consolidated Financial Results for the Year Ended March 31, 2015; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2016

Daiichi Sankyo Company, Limited reported consolidated and non-consolidated financial results for the year ended March 31, 2015. For the year, the consolidated company reported revenue of JPY 919,372 million against JPY 899,126 million a year ago. Operating profit was JPY 74,422 million against JPY 112,922 million a year ago. Profit before tax was JPY 79,936 million against JPY 112,950 million a year ago. Profit attributable to owners of the company was JPY 322,119 million against JPY 60,943 million a year ago. Diluted earnings per share was JPY 456.62 against JPY 86.41 a year ago. Return on equity attributable to owners of the company was 28.2% against 6.5% a year ago. Net cash flows from operating activities was JPY 142,776 million against JPY 37,304 million a year ago. Significant factors contributing to the year-on-year decline in operating profit included a decline in gross profit caused by JPY 35.0 billion of impairment of the commercial rights for the anticancer agent Zelboraf owned by consolidated subsidiary Plexxikon Inc. and expenses of JPY 13.9 billion associated with the restructuring of Group operations in Japan. Profit from continuing operations declined by JPY 22.2 billion, or 33.8% year on year, to JPY 43.6 billion against JPY 65,792 million a year ago. Acquisitions of property, plant and equipment was JPY 38,500 million against JPY 36,388 million a year ago. Acquisition of intangible assets was JPY 56,130 million against JPY 4,704 million a year ago. For the year, the non-consolidated company reported revenue of JPY 622,424 million against JPY 618,179 million a year ago. Operating profit was JPY 23,347 million against JPY 65,528 million a year ago. Ordinary income was JPY 30,686 million against JPY 99,554 million a year ago. Net income was JPY 266,569 million against JPY 64,452 million a year ago. Diluted earnings per share was JPY 377.88 against JPY 91.38 a year ago. Net assets per share was JPY 1,523.23 against JPY 1,167.94 a year ago. For the year ending March 31, 2016, the company expects consolidated revenue of JPY 920,000 million, operating profit of JPY 100,000 million, profit before tax of JPY 95,000 million and profit attributable to owners of the company of JPY 60,000 million or JPY 85.22 per basic share.

Daiichi Sankyo Company, Limited to Report Fiscal Year 2015 Results on May 14, 2015

Daiichi Sankyo Company, Limited announced that they will report fiscal year 2015 results at 1:00 PM, Tokyo Standard Time on May 14, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4568:JP ¥2,359.50 JPY +11.50

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $7.64 USD -0.10
BioCryst Pharmaceuticals Inc $11.17 USD -0.15
BioMerieux €103.65 EUR -0.30
Infinity Pharmaceuticals Inc $13.13 USD +0.01
Ipsen SA €49.90 EUR -0.42
View Industry Companies

Industry Analysis


Industry Average

Valuation 4568 Industry Range
Price/Earnings 34.4x
Price/Sales 1.7x
Price/Book 1.2x
Price/Cash Flow 5.0x
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAIICHI SANKYO CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at